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Abstract Through the use of QuantiFERON-TB Gold, a
commercial IFN-c assay, we compared differences in
quantitative T-cell responses to Mycobacterium tubercu-
losis (MTB)-speciﬁc antigens [QuantiFERON TB-2G
(QFT-2G)] between patients with active tuberculosis (TB)
disease and those with latent TB infection (LTBI). The
patient group consisted of 180 patients with active TB
disease (culture-positive for MTB) and 50 screening con-
tacts with LTBI-positive response to the QFT-2G test. We
prospectively performed a tuberculin skin test (TST) and a
QFT-2G test for all subjects. The median IFN-c levels upon
the application of both antigens, ESAT-6 and CFP-10, were
signiﬁcantly higher in patients with active TB disease than
in those with LTBI. A combined positive response to both
antigens occurred at a higher rate in patients with active TB
disease than in those with LTBI. There were no signiﬁcant
relationships between the quantitative responses of IFN-c
to both antigens and the maximum induration on TST in
both patient groups. We demonstrated signiﬁcant differ-
ences in the quantitative responses of IFN-c to MTB
between patients with active TB disease and those with
LTBI in this study. However, there was an overlap in the
IFN-c levels between active TB disease and LTBI groups.
Therefore, it would be difﬁcult to use the QFT-2G test to
completely discriminate active TB disease from LTBI.
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Introduction
ThedevelopmentofT-cell-basedinterferon-gamma(IFN-c)
assays (IGRAs) for Mycobacterium tuberculosis (MTB)-
speciﬁc antigens represents a signiﬁcant advance that is
expected to replace the tuberculin skin test (TST) in
screening for active TB disease or latent tuberculosis infec-
tion (LTBI) [1–3]. These IGRAs have demonstrated excel-
lent speciﬁcity and shown a closer correlation with the
exposure gradient than the TST [4–6]. However, it is gen-
erallyassumedthatthesetests,likeTST,cannotdiscriminate
between active TB disease and LTBI. There are some limi-
tations to the use of IGRAs in serial testing. The utility of
these assays for monitoring disease activity and treatment
response, or as predictors of the progression of LTBI to
active TB disease, is currently the subject of ongoing
research.
Two commercial IGRAs have recently become avail-
able, QuantiFERON-TB Gold In-Tube(Cellestis Ltd.,
Victoria, Australia) with ELISA used to measure IFN-c
concentrations in supernatants, and the T-SPOT.TB test
(Oxford Immunotec, Oxford, UK) with an enzyme-linked
immunospot (ELISPOT) assay used to detect individual T
cells producing IFN-c [1, 7]. QuantiFERON TB-2G (QFT-
2G) is commonly used for the diagnosis of active TB
disease or LTBI, but T-SPOT.TB or QFT Gold In-Tube has
not yet been approved in Japan. We therefore compared
quantitative T-cell responses to MTB-speciﬁc antigens
between cohorts of contacts with LTBI and patients with
active TB disease using the commercial QFT-2G test.
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Study Population
One hundred eighty patients conﬁrmed to be positive for
MTB on culture of sputum, bronchoalveolar lavage ﬂuid,
peritoneal ﬂuid, or lymph node tissue samples and a cohort
of 50 screening contacts with LTBI (positive QFT-2G
response with or without a positive TST result) drawn from
the community were prospectively enrolled starting in Jan-
uary 2005. Screening contacts with LTBI all had exposure
histories totheir index case 8–12 weeks earlier and all index
cases were smear- and culture-positive for MTB using
sputum specimens. However, none of these subjects with
LTBI showed any clinical symptoms (fever, cough, or
sputum), abnormal inﬂammatory responses, or abnormal
radiological ﬁndings suggesting pulmonary TB. This study
was approved by the institutional ethical committee at each
hospital. Patients were diagnosed at Kawasaki Medical
School Hospital and four afﬁliated hospitals. All patients
with active TB disease showed negative ﬁndings on
enzyme-linked immunosorbent assay (ELISA) testing for
HIV. Regarding subjects screened for contact with the index
case, HIV testing was not performed, but subjects with a
history of HIV infection were excluded from data analyses.
Demographic data from patients with active TB disease and
screening contacts with LTBI were collected, including any
history of previous TB or antituberculous treatment, other
underlying diseases, and administration of immunosup-
pressive drugs within 3 months before enrolment in this
study.
Sample Collection and TST
A heparinized blood sample was collected by venipuncture
from each patient for whole-blood IFN-c assay. Blood
samples were collected before administration of the Man-
toux TST. For the TST, 0.1 ml of tuberculin PPD [Nippon
BCG, equivalent to three tuberculin units (TU) of puriﬁed
protein derivative solution (PPD-S)] was injected intra-
dermally into the volar aspect of the forearm, and the
transverse induration diameter was measured 48 h later.
The results of the test were interpreted by hospital staff
based on the patient’s degree of risk, according to current
guidelines [8]. A lower cutoff of 5 mm for a positive test
was used for individuals.
QFT-2G Test
The QFT-2G test was performed according to the manu-
facturer’s recommendations, and the test result was judged
according to CDC guidelines [1]. The test result was con-
sidered positive if the IFN-c level in the sample well after
stimulation with ESAT-6 and/or CFP-10 was C0.35 IU/ml,
irrespective of the result for the positive control well. The
test was considered negative if the IFN-c level was
\0.35 IU/ml and the IFN-c level of the positive control
well was C0.35 IU/ml. The test result was considered
indeterminate if the IFN-c level was \0.35 IU/ml in both
antigen wells and\0.5 IU/ml in the positive control well.
The QFT-2G test was performed for all patients before
initiating the administration of antituberculous drugs.
Statistical Analysis
Data were input into Excel 2000 (Microsoft Corp., Red-
mond, WA) and then transferred to Santa software, version
7.0 (Santa, Vienna, Austria), for statistical analysis. Pear-
son’s v
2 test was used to compare data from the two groups
and McNemar’s test was used to compare paired data. The
Mann–Whitney U test was used to compare unpaired data.
The level of signiﬁcance was P\0.05.
Results
One hundred thirty subjects screened after contact with
index cases were included in this study protocol. They
consisted of 70 males and 60 females, and the mean age
was 41.8 ± 9.8 years (range = 18–76). The previous his-
tory of TST was unreliable in most subjects. Ninety sub-
jects (69%) had a history of BCG vaccination. The
comparison of TST and QFT-2G test results for all contacts
screened is shown in Table 1. The TST induration diameter
was larger than 5 mm in 78 (60%) subjects, and 50 (38%)
showed positive QFT-2G test results. While both TST and
QFT-2G tests were positive in 34 screening contacts
(26%), only the QFT-2G test was positive in 16 (12%) and
only the TST was positive in 44 (34%). Of all screening
contacts, 50 subjects (38%) fulﬁlled the inclusion criteria
for LTBI in this study.
A comparison of TST and QFT-2G test results for
patients with active TB disease is shown in Table 2. The
positive response rate on TST did not signiﬁcantly differ
between all subjects screened after contact (60%) and those
Table 1 Comparison of TST and QFT-2G test results for all contacts
screened (130 cases)
QFT-2G test TST
Positive Negative Total
Positive 34 (26%) 16 (12%) 50 (38%)
Negative 44 (34%) 31 (24%) 75 (58%)
Indeterminate 0 5 (4%) 5 (4%)
Total 78 (60%) 52 (40%) 130 (100%)
TST tuberculin skin test, QFT-2G QuantiFERON TB-2G
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123with active TB disease (63%). The positive response rate to
the QFT-2G test was signiﬁcantly higher in patients with
active TB disease (83%) than in all screening contacts
(38%). The positive response rate to the QFT-2G test
(83%) was signiﬁcantly higher than to the TST (63%) in
patients with active TB disease. The positive response rate
to the QFT-2G test (38%) was signiﬁcantly lower than to
the TST (60%) in all screening contacts.
In 180 patients with active TB disease, acid-fast smear
results of samples were positive in 93 patients (52%) and
negative in the remaining 87 patients.
The clinical characteristics of the 50 screening contacts
with LTBI and the 180 patients with active TB disease are
shown in Table 3. There were no signiﬁcant differences in
the clinical characteristics between LTBI and active TB
disease patients except for age, sex, and underlying disease
including respiratory disease.
Concerning the comparison of QFT-2G test results
related to combined and separate responses to ESAT-6 and
CFP-10 antigens for LTBI and active TB disease, the
positive response rate for both ESAT-6 and CFP-10 anti-
gens was signiﬁcantly lower in community contacts with
LTBI than that in patients with active TB disease. The
positive response rates for ESAT-6 only and for CFP-10
only were lower in patients with active TB disease than in
screening contacts with LTBI (Table 4).
The IFN-c level in the response to ESAT-6 and CFP-10
antigens for screening contacts with LTBI and patients
with active TB disease is shown in Table 5. The IFN-c
levels for ESAT-6 and CFP-10 antigens were signiﬁcantly
higher in patients with active TB disease (IFN-c level for
ESAT-6: 1.24 ± 0.30 IU/ml, IFN-c level for CFP-10:
1.58 IU/ml) than in screening contacts with LTBI (IFN-c
level for ESAT-6: 0.61 ± 0.20 IU/ml, IFN-c level for
CFP-10: 0.72 ± 0.21 IU/ml).
Discussion
We noted a signiﬁcant reduction in the positive response
rate for both ESAT-6 and CFP-10 antigens in screening
contacts with LTBI than in patients with active TB disease,
and the quantitative T-cell responses to ESAT-6 and CFP-
10 antigens were signiﬁcantly higher in patients with active
TB disease than in those with LTBI using the QFT-2G
assay.
In previous reports, Janssens et al. [9] and Chee et al.
[10] reported a signiﬁcant difference in the quantitative
values of T-SPOT.TB responses between active TB cases
and contacts with positive T-SPOT.TB responses, with a
large overlap in the range of values. Although Chee et al.
[10] did not identify a signiﬁcant difference in the quan-
titative values using the QFT Gold-In-Tube assay in pre-
vious reports, we found a signiﬁcant difference in
quantitative QFT-2G responses between the two groups in
this study, consistent with the ﬁndings in a previous report
by Higuchi et al. [11]. Higuchi et al. [11] also indicated that
the geometric mean of the IFN-c production level in the
active TB disease group was signiﬁcantly larger than that
in the LTBI group, and the combined parameters of ESAT-
6 and CFP-10 signiﬁcantly contribute to the active TB
disease risk for infected subjects using the QFT-2G test.
Differences in the sensitivity of T-SPOT.TB and QFT-2G
assays in immunocompromised patients have been well
reported [4]. Although both assays measure T-cell IFN-c
responses to the Mycobacterium tuberculosis (MTB)-spe-
ciﬁc antigens ESAT-6 and CFP-10 after overnight stimu-
lation, the measurement of IFN-c levels in whole blood in
the QFT-2G assay [as opposed to measuring the number of
IFN-c-producing T cells in a standardized number of
peripheral blood mononuclear cells (PBMCs) using
T-SPOT.TB] may render this assay less sensitive than
T-SPOT.TB. Regardless of this hypothesis, there was a
signiﬁcant difference in quantitative QFT-2G responses
between active TB cases and screening contacts with LTBI
in this study.
While the median IFN-c level in response to ESAT-6
and CFP-10 antigens in patients with active TB disease was
more than two times higher than that of screening contacts
with LTBI, the large overlap in the range of values between
these two groups suggests that isolated QFT-2G results
would not be useful as a diagnostic method to discriminate
between active TB disease and LTBI.
There are several limitations to this study. First, because
there is no gold standard for the diagnosis of LTBI, cases
with active TB disease may have been missed among
screening contacts with presumed LTBI. However, this is
highly unlikely since all of the subjects demonstrated
normal clinical and radiological ﬁndings. Indeed, there
were no missed cases of active TB disease detected during
the subsequent 3 years of follow-up.
Second, because there were signiﬁcant differences in the
frequency of patients with underlying disease and mean
age of both groups (Table 3), these factors have inﬂuenced
Table 2 Comparison of TST and QFT-2G test results for patients
with active TB disease (180 cases)
QFT-2G test TST
Positive Negative Total
Positive 114 (63%) 36 (20%)
Negative 0 11 (6%)
Indeterminate 0 19 (11%)
Total 114 (63%) 66 (37%)
TST tuberculin skin test, QFT-2G QuantiFERON TB-2G
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123the quantitative response of IFN-c for both MTB-speciﬁc
antigens in this study.
Third, the present deﬁnition of LTBI is arbitrary.
Indeed, there is no gold standard for deﬁning LTBI. IGRA
results correlate better with exposure than TST results; the
lifetime risk of active TB disease based on IGRA results
only currently remains unknown [12]. The clinical situation
resulting from the present CDC recommendations was
investigated [1]; subjects considered as having probable
LTBI were detected by a positive QFT-2G test result
Table 3 Clinical
characteristics of 50 screening
contacts with latent tuberculosis
infection (LTBI) and 180
patients with active tuberculosis
(TB) disease
a With hemodialysis
b All patients received
corticosteroid therapy
Clinical characteristics LTBI (n = 50) Active TB disease
(n = 180)
P value
Age (years) (mean ± SD) 41.6 ± 9.5 63.8 ± 10.6 0.010
Sex (Male:Female) 24:26 140:40 0.022
Smoking history 30 (60%) 120 (67%) 0.768
Alcohol abuse history 6 (12%) 32 (18%) 0.356
Underlying disease 18 (36%) 133 (74%) 0.035
Respiratory disease 5 (12%) 61 (34%) 0.038
Healed pulmonary TB 0 (0%) 20 (11%) 0.008
COPD 2 (4%) 13 (7%) 0.320
Others 4 (8%) 28 (16%) 0.101
Nonrespiratory disease 13 (26%) 72 (40%) 0.070
Gastrointestinal disease 4 (8%) 18 (10%) 0.755
Diabetes mellitus 3 (6%) 15 (8%) 0.842
Cancer 1 (2%) 14 (8%) 0.084
Cardiovascular disease 3 (6%) 13 (7%) 0.893
Collagen vascular disease 1 (2%) 7 (4%) 0.396
Chronic renal failure
a 0 (0%) 5 (3%) 0.108
Immunosuppressive treatment
b 1 (2%) 13 (10%) 0.061
Received BCG vaccination 34 (63%) 116 (64%) 0.867
Received TB treatment 0 (0%) 29 (16%) 0.008
Laboratory data
WBC count (cells/ll) 4620 ± 543 4058 ± 518 0.350
Lymphocyte count (cells/ll) 1036 ± 92 916 ± 87 0.402
Total protein (g/dl) 6.9 ± 1.0 6.4 ± 0.8 0.346
Albumin (g/dl) 3.7 ± 0.8 3.3 ± 0.6 0.367
Table 4 Comparison of the QFT-2G test results related to the combined and separate responses to ESAT-6 and CFP-10 antigens for patients
with LTBI and active TB disease
QFT-2G test LTBI (n = 50) Active TB disease
(n = 180)
P value
ESAT-6 only positive 22 (44%) 49 (27%) 0.077
CFP-10 only positive 24 (48%) 51 (28%) 0.048
ESAT-6 and CFP-10 positive 4 (8%) 50 (28%) 0.026
Total 50 (100%) 150 (83%) 0.564
QFT-2G QuantiFERON TB-2G
Table 5 IFN-c level (U/ml) in response to ESAT-6 and CFP-10 antigens for patients with LTBI and active TB disease
QFT-2G test LTBI (n = 50) Active TB disease (n = 180) P value
ESAT-6 0.61 ± 0.20 (0.35–4.25) 1.24 ± 0.30 (0.20–10.62) 0.010
CFP-10 0.72 ± 0.21 (0.35–4.60) 1.58 ± 0.36 (0.24–11.90) 0.008
QFT-2G QuantiFERON TB-2G
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123despite negative TST results. Although the T-SPOT.TB test
has been used as an IGRA, Janssens et al. [9] indicated that
studyingonlyT-SPOT.TB-positivesubjectsorT-SPOT.TB-
and TST-positive subjects did not signiﬁcantly alter the
results according to prevailing guidelines.
Fourth, we used the QFT-2G test as an IGRA in this
study because the QFT-2G assay is currently the only
IGRA commercially available in Japan. Newer commercial
assays such as T-SPOT.TB (Oxford-Immunotec) and
QuantiFERON-TB Gold In-Tube (Cellestis) have many
differences and may provide higher levels of sensitivity
[13]. Indeed, Harada et al. [14] reported that the sensitivity
of the QFT Gold In-Tube test (93%) was signiﬁcantly
higher than that of the QFT-2G test (81%), although the
speciﬁcities of both tests were the same (99%). We think
that the QFT Gold In-Tube or T-SPOT.TB should be
approved and made commercially available for the sup-
portive diagnosis of active TB disease and LTBI.
In conclusion, we demonstrated signiﬁcant differences
in the quantitative responses of IFN-c to MTB between
patients with active TB disease and those with LTBI in this
study. However, there is an overlap in the IFN-c levels
between active TB disease and LTBI groups. Therefore, it
would be difﬁcult to use the QFT-2G test to completely
discriminate active TB disease from LTBI. A large-scale
longitudinal study that investigates this important potential
use of IGRAs test is awaited.
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